Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 33Carcinoma, Non-Small-Cell Lung 19Squamous Cell Carcinoma of Head and Neck 18Esophageal Neoplasms 17Uterine Cervical Neoplasms 11Nasopharyngeal Carcinoma 11Head and Neck Neoplasms 11Pancreatic Neoplasms 9Oropharyngeal Neoplasms 8Esophageal Squamous Cell Carcinoma 6Carcinoma, Squamous Cell 6Stomach Neoplasms 4Neoplasms 4Mouth Neoplasms 4Glioblastoma 4Colorectal Neoplasms 4Carcinoma 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Pathologic Complete Response 3Hypopharyngeal Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms by Site 2Nasopharyngeal Neoplasms 2NSCLC 2Lymphoma 2Lung Neoplasms 2Locally Advanced Malignant Neoplasm 2Laryngeal Neoplasms 2

Interventions

trilaciclib 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myelosuppression × Chemoradiotherapy × Clear all
NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡